实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2015年
4期
616-619
,共4页
刘墨%杨树法%王海林%顾朋%黄伍奎%樊喜文
劉墨%楊樹法%王海林%顧朋%黃伍奎%樊喜文
류묵%양수법%왕해림%고붕%황오규%번희문
经导管肝动脉化疗栓塞%经皮射频消融术%中晚期肝癌%预后
經導管肝動脈化療栓塞%經皮射頻消融術%中晚期肝癌%預後
경도관간동맥화료전새%경피사빈소융술%중만기간암%예후
Transcatheter arterial chemoembolization(TACE)%Radio frequency ablation(RFA)%Middle and advanced hepatocellular carcinoma%Prognosis
目的:探讨经导管肝动脉化疗栓塞(TACE)联合经皮射频消融术(RFA)治疗中晚期肝癌的临床疗效及安全性并分析影响预后因素。方法将中晚期原发性肝癌患者128例分为肝动脉化疗栓塞组( TACE组)与肝动脉化疗栓塞联合经皮射频消融术( RFA)组( TACE+RFA组),各64例。 TACE组患者行一次或多次单一肝动脉化疗治疗;TACE+RFA组在肝动脉化疗治疗结束后1~2周再行经皮射频消融术治疗。结果 TACE组与TACE+RFA组总有效率分别为68.75%(44/64)、95.31%(61/64);中位生存时间分别为13与18个月;TACE+RFA组1年生存率为73.4%(47/64),2年生存率为20.3%(13/64),而TACE组分别为56.25%(36/64)和7.81%(5/64);预后影响因素分析结果显示肿瘤数量、分期、直径、血清甲胎蛋白水平等与患者预后有相关性。结论经导管肝动脉化疗栓塞( TACE)联合经皮射频消融术( RFA)治疗原发性中晚期肝癌可以有效提高患者生存率,延长患者的生存期,其肿瘤数量、分期、直径等4项指标是影响患者预后的危险因素。
目的:探討經導管肝動脈化療栓塞(TACE)聯閤經皮射頻消融術(RFA)治療中晚期肝癌的臨床療效及安全性併分析影響預後因素。方法將中晚期原髮性肝癌患者128例分為肝動脈化療栓塞組( TACE組)與肝動脈化療栓塞聯閤經皮射頻消融術( RFA)組( TACE+RFA組),各64例。 TACE組患者行一次或多次單一肝動脈化療治療;TACE+RFA組在肝動脈化療治療結束後1~2週再行經皮射頻消融術治療。結果 TACE組與TACE+RFA組總有效率分彆為68.75%(44/64)、95.31%(61/64);中位生存時間分彆為13與18箇月;TACE+RFA組1年生存率為73.4%(47/64),2年生存率為20.3%(13/64),而TACE組分彆為56.25%(36/64)和7.81%(5/64);預後影響因素分析結果顯示腫瘤數量、分期、直徑、血清甲胎蛋白水平等與患者預後有相關性。結論經導管肝動脈化療栓塞( TACE)聯閤經皮射頻消融術( RFA)治療原髮性中晚期肝癌可以有效提高患者生存率,延長患者的生存期,其腫瘤數量、分期、直徑等4項指標是影響患者預後的危險因素。
목적:탐토경도관간동맥화료전새(TACE)연합경피사빈소융술(RFA)치료중만기간암적림상료효급안전성병분석영향예후인소。방법장중만기원발성간암환자128례분위간동맥화료전새조( TACE조)여간동맥화료전새연합경피사빈소융술( RFA)조( TACE+RFA조),각64례。 TACE조환자행일차혹다차단일간동맥화료치료;TACE+RFA조재간동맥화료치료결속후1~2주재행경피사빈소융술치료。결과 TACE조여TACE+RFA조총유효솔분별위68.75%(44/64)、95.31%(61/64);중위생존시간분별위13여18개월;TACE+RFA조1년생존솔위73.4%(47/64),2년생존솔위20.3%(13/64),이TACE조분별위56.25%(36/64)화7.81%(5/64);예후영향인소분석결과현시종류수량、분기、직경、혈청갑태단백수평등여환자예후유상관성。결론경도관간동맥화료전새( TACE)연합경피사빈소융술( RFA)치료원발성중만기간암가이유효제고환자생존솔,연장환자적생존기,기종류수량、분기、직경등4항지표시영향환자예후적위험인소。
Objective To evaluate the efficacy of transcatheter arterial chemoembolization( TACE) combined with radio-frequency ablation( RFA) for middle and advanced hepatocellular carcinoma and prognostic factors.Methods 128 patients with middle and advanced hepatocellular carcinoma were divided into 2 groups,each with 64 patients.TACE group were given TACE one or several times,TACE+RFA group were given RFA 1~2 weeks after TACE.Results In TACE group and TACE+RFA group,the total effective rates were 68.75%(44/64) and 95.31% (61/64),the median survival time were 13 months and 18 months.The 1-and 2-year survival rates in the TACE+RFA group were 73.4%(47/64) and 20.3%(13/64) .The 1-and 2-year survival rates in the TACE group were 56.25%(36/64) and 7.81%(5/64).Tumor number,staging,diameter and level of AFP were related with prognosis.Conclusion TACE combined with RFA can significantly increase survival rate and prolong survival period of patients,tumor number,staging,diameter and level of AFP are risk factors affecting prognosis.